Abstracts & Presentations
Eric Burks (view biography)
– Pulmonary Immunopathology of COVID-19 Induced Diffuse Alveolar Damage: The utility of multiplex immunohistochemistry
– Multiplex IHC as a means to aide in the assessment of minimal residual disease (MRD)
for plasma cell neoplasms.
Hazel Chambers-Smith (view biography)
– The role of immunohistochemistry in the diagnosis of paediatric brain tumours
Bron Christiansen (view biography)
– Technical test approach: the pre-analytical phase
Regan Fulton (view biography)
– Immunohistochemistry assay validation: College of American Pathologists Guidelines
David Gan (view biography)
– MOCKTALES: A Mock RCPAQAP IHC Assessment
Zenobia Haffajee (view biography)
– Keeping ABREAST of your EQA results. Breast Markers Review – An RCPAQAP update.
Emiel Janssen (view biography)
– Molecular biomarkers in endometrial hyperplasia
– IHC and molecular diagnostics in non-small cell lung carcinoma
Julia Pagliuso (view biography)
– RCPA-QAP-external quality assessment update
MOCKTALES: A Mock RCPAQAP IHC Assessment
David Gan (view biography)
Supervisor of the Special Stains area in Anatomical Pathology
QML Pathology
This presentation will attempt to clear up a few myths about assessments as well as include the audience in a mock assessment to get a better understanding of the process.
Back to Top of Page
Keeping ABREAST of your EQA results. Breast Markers Review – An RCPAQAP update.
Zenobia Haffajee (view biography)
Senior Scientist
Royal College of Pathologists of Australasia
Quality Assurance Program, Anatomical Pathology
St Leonards, NSW, Australia
RCPAQAP provides EQA assessment for proficiency testing for Immunohistochemistry (IHC) and bright field in situ hybridization (ISH) techniques for the detection of breast tumour markers. This specific EQA determines the quality of Oestrogen (ER), Progesterone (PR), HER2 IHC and HER2 ISH staining on formalin fixed paraffin-embedded tumour sections.
The Breast markers EQA pilot was implemented in 2002. This presentation is an overview of data collated over a period of 17 years and highlights the survey results and participant performance.
In keeping with the updated recommended ASCO/CAP guidelines from the RCPA, laboratories are recommended to ensure that their methods area validated against a reference method and that the assays performance is continuously monitored to identify any potential issues. This may have the potential to affect patient treatment.
Back to Top of Page
RCPA-QAP-external quality assessment update
Julia Pagliuso (view biography)
The Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP), Anatomical Pathology,
St Leonards, NSW, 2065,
Australia
The Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) provides world-class, peer-reviewed External Quality Assurance (EQA) programs and continuing professional education. Our programs are offered in Australia and internationally in over 80 countries. Our strength lies in the expertise and support provided by an extensive advisory network consisting of pathologists and scientific staff from Australia and internationally.
The RCPAQAP has undergone a number of changes over the last few years and is continuing to evolve. These changes will be communicated, along with a summary of the future directions and projects for the Anatomical Pathology discipline.
Changes discussed will include:
- Informatics – new myQAP portal
- Changes to programs –HER2 ISH (Bright field)
- Online product catalogue – advertising of antibodies/stains for next year
- New initiatives – PD-L1 NSCLC Interpretation, PDL-1 triple negative breast cancer, FISH
RCPAQAP is committed to provide an efficient and customer focused service to participants and feedback is welcome. RCPAQAP staff will be available to answer any questions during breaks.
Back to Top of Page
Technical test approach: the pre-analytical phase
Bron Christiansen (view biography)
The Royal Children’s Hospital
Parkville, VIC, Australia
Back to Top of Page
Immunohistochemistry assay validation: College of American Pathologists Guidelines
Regan Fulton (view biography)
Array Science, LLC
475 Gate 5 Road, #100
Sausalito, CA 94965, USA
Back to Top of Page
Molecular biomarkers in endometrial hyperplasia
Emiel Janssen (view biography)
Stavanger University and Stavanger University Hospital
Department of Pathology
Stavanger, Norway
The morphometric Dscore appears to be most reproducible of all existing prognostic classifications and prognostically to be the strongest.2 However, the computerized morphometric analysis technology that is required for D-score assessment is not available widely at the moment.
Although this will most likely change with the advent of digital pathologic evaluation, it would be preferable to have strong molecular immunohistochemical outcome predictors. An historic overview on the development and background for the D.score will be provided, furthermore the role of other immunhistochemical and molecular markers that can support EIN classification will be presented.
Back to Top of Page
IHC and molecular diagnostics in non-small cell lung carcinoma
Emiel Janssen (view biography)
Stavanger University and Stavanger University Hospital
Department of Pathology
Stavanger, Norway
Back to Top of Page
Pulmonary Immunopathology of COVID-19 Induced Diffuse Alveolar Damage: The utility of multiplex immunohistochemistry
Eric Burks (view biography)
Clinical Associate Professor of Pathology
Boston University School of Medicine
Back to Top of Page
Multiplex IHC as a means to aide in the assessment of minimal residual disease (MRD)
for plasma cell neoplasms.
Eric Burks (view biography)
Clinical Associate Professor of Pathology
Boston University School of Medicine
Back to Top of Page
The role of immunohistochemistry in the diagnosis of paediatric brain tumours
Hazel Chambers-Smith (view biography)
Senior Scientist
The Royal Children’s Hospital, Department of Anatomical Pathology
Parkville, VIC. Australia
Back to Top of Page
Last update on: 2022/04/26 11:12:34 UTC/GMT time.